

Cardiac Biomarkers Market Forecasts to 2034 – Global Analysis By Product Type (B-Type Natriuretic Peptide (BNP), Creatine Kinase-Muscle/Brain (CK-MB) and Other Product Types), By Location of Testing (Point-of-care Testing and Laboratory Testing), Application, End User and By Geography

<https://marketpublishers.com/r/C87DB9BB05EDEN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: C87DB9BB05EDEN

Abstracts

According to Statistics MRC, the Global Cardiac Biomarkers Market is accounted for \$29.6 billion in 2026 and is expected to reach \$101.2 billion by 2034 growing at a CAGR of 16.6% during the forecast period. Cardiac biomarkers are specific molecules or proteins released into the bloodstream due to heart injury, damage or stress. These biomarkers, such as troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP), are used in diagnostics to indicate heart-related conditions. Their detection and levels aid in diagnosing heart attacks, heart failure or other cardiac diseases, guiding treatment decisions and assessing cardiac health.

According to the World Health Organization (WHO), 77 million adults above 18 years have type 2 diabetes, with 25 million prediabetics. This increases cardiovascular disease risk and puts additional pressure on the health system.

Market Dynamics:

Driver:

Rising cardiovascular diseases

With an increasing global burden of heart-related conditions like heart attacks, heart

failure and cardiac ischemia, there's a growing demand for reliable diagnostic tools. Cardiac biomarkers serve as vital indicators, aiding in the early detection, diagnosis, and prognosis of cardiovascular ailments. Their ability to accurately assess heart health, predict risks, and guide treatment strategies aligns with the pressing need for efficient, timely, and precise diagnostics in combating the rising incidence of cardiovascular diseases worldwide.

Restraint:

Stringent regulations

Stringent regulations pose a restraint on cardiac biomarker development and implementation. The rigorous approval processes set by regulatory bodies demand extensive clinical validation, often prolonging the time-to-market for new biomarkers. These stringent guidelines necessitate comprehensive studies to ensure accuracy, sensitivity and specificity in detecting cardiac conditions. Compliance with these regulations involves significant investment in research, clinical trials, and meeting specific performance criteria, leading to increased costs and time constraints.

Opportunity:

Increasing focus on point-of-care testing

Point-of-care tests allow for rapid and convenient on-site diagnostics, offering immediate results without the need for sending samples to a central laboratory. In cardiac care, this facilitates quicker detection of biomarkers like troponins, enabling faster diagnosis of heart conditions such as heart attacks. This shift enhances patient care by expediting treatment decisions, especially in emergency settings and supports healthcare systems by reducing turnaround times and improving overall efficiency in managing cardiac emergencies.

Threat:

Emergence of alternative diagnostic methods

New technologies, such as advanced imaging techniques or point-of-care testing devices, might offer rapid, non-invasive and possibly more cost-effective ways to assess cardiac health. These alternatives could challenge the dominance of traditional biomarker testing, impacting market adoption and preferences among healthcare

providers.

Covid-19 Impact:

The COVID-19 pandemic influenced cardiac biomarker testing by diverting healthcare resources towards managing the virus. Reduced non-COVID medical visits led to fewer cardiac evaluations, impacting biomarker testing frequency. Additionally, some COVID patients experienced cardiac complications, increasing the demand for biomarker assessments. The pandemic's strain on healthcare systems altered priorities, affecting cardiac biomarker utilisation and emphasising the need for adaptable diagnostic strategies during health crises.

The troponins segment is expected to be the largest during the forecast period

The troponins segment is projected to dominate due to its widespread use as a highly sensitive and specific cardiac biomarker for diagnosing heart-related conditions. Troponins, especially troponin I and troponin T, exhibit superior sensitivity in detecting myocardial injury, notably for diagnosing heart attacks. The growing prevalence of cardiovascular diseases globally and the increasing adoption of troponin testing in routine clinical practice contribute to its anticipated prominence, making it the largest segment in cardiac biomarker testing during the forecast period.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is poised for substantial growth due to increased patient access to advanced healthcare services and diagnostic facilities in hospital settings. Hospitals serve as primary centres for acute care, where cardiac biomarker testing plays a pivotal role in diagnosing heart-related conditions. Rising incidences of cardiovascular diseases and the need for timely and accurate diagnostics within hospital environments contribute to the segment's anticipated growth.

Region with largest share:

North America's anticipated dominance in the cardiac biomarkers market is attributed to well-established healthcare infrastructure, technological advancements and high healthcare spending. The region's robust research and development activities, along with the presence of key market players, contribute to its significant market share. Additionally, the high prevalence of cardiovascular diseases, coupled with increasing awareness and adoption of advanced diagnostic techniques, drives market growth.

Region with highest CAGR:

The Asia-Pacific region is poised for substantial growth in the cardiac biomarker market due to the increasing prevalence of cardiovascular diseases, a rising ageing population and improving healthcare infrastructure. The region witnesses a growing awareness of cardiac health, driving demand for advanced diagnostic tools. Additionally, initiatives by governments and healthcare organisations to enhance cardiac care contribute to the market's expansion. The increasing adoption of cardiac biomarkers in countries like China and India, along with advancements in healthcare technologies, positions the Asia-Pacific region for significant market growth.

Key players in the market

Some of the key players in Cardiac Biomarkers Market include Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company (BD), BG Medicine, Bio-Rad Laboratories, Corgenix, Fujirebio, Hologic, Meso Scale Diagnostics (MSD), Mindray, Ortho Clinical Diagnostics, Pathkind Labs, Qiagen, Randox Laboratories, R-Biopharm AG, Response Biomedical, Roche Diagnostics, Siemens Healthineers, Singulex Inc, SRL Diagnostics, Thermo Fisher Scientific and Trinity Biotech.

Key Developments:

In October 2023, Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued by the global medical devices and solutions provider.

In January 2023, Pathkind Labs, Roche Diagnostics partner to release cardiac biomarker. This announcement of NTProBNP comes in light of the growing burden of heart failure among T2D patients in India, inciting the need for urgent action. NTProBNP can directly predict adverse outcomes and cardiovascular mortality and can evaluate the overall status of a patient with type 2 diabetes to facilitate the establishment of correct therapy management and follow-up.

In September 2022, SRL Diagnostics launched 'Heart Assure,' a specialized test that can predict the risk of a cardiac event in an individual. High-sensitivity troponin I is a simple blood test that can precisely predict a cardiac injury by providing a heart health

risk score.

Product Types Covered:

B-Type Natriuretic Peptide (BNP)

Creatine Kinase-Muscle/Brain (CK-MB)

High-Sensitivity C-Reactive Protein (hs-CRP)

Myoglobin

Troponins

Other Product Types

Location of Testings Covered:

Point-of-care Testing

Laboratory Testing

Applications Covered:

Myocardial Infarction

Congestive Heart Failure

Acute Coronary Syndrome

Other Applications

End Users Covered:

Diagnostic Laboratories

Hospitals

Pharmaceutical and Biotechnology Companies

Research Institutions

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment

Opportunities, and recommendations)

- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL CARDIAC BIOMARKERS MARKET, BY PRODUCT TYPE

- 5.1 Introduction
- 5.2 B-Type Natriuretic Peptide (BNP)
- 5.3 Creatine Kinase-Muscle/Brain (CK-MB)
- 5.4 High-Sensitivity C-Reactive Protein (hs-CRP)
- 5.5 Myoglobin
- 5.6 Troponins
- 5.7 Other Product Types

6 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING

- 6.1 Introduction
- 6.2 Point-of-care Testing
- 6.3 Laboratory Testing

7 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION

- 7.1 Introduction
- 7.2 Myocardial Infarction
- 7.3 Congestive Heart Failure
- 7.4 Acute Coronary Syndrome
- 7.5 Other Applications

8 GLOBAL CARDIAC BIOMARKERS MARKET, BY END USER

- 8.1 Introduction
- 8.2 Diagnostic Laboratories
- 8.3 Hospitals
- 8.4 Pharmaceutical and Biotechnology Companies
- 8.5 Research Institutions
- 8.6 Other End Users

9 GLOBAL CARDIAC BIOMARKERS MARKET, BY GEOGRAPHY

- 9.1 Introduction
- 9.2 North America
 - 9.2.1 US

- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 Italy
 - 9.3.4 France
 - 9.3.5 Spain
 - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
 - 9.4.1 Japan
 - 9.4.2 China
 - 9.4.3 India
 - 9.4.4 Australia
 - 9.4.5 New Zealand
 - 9.4.6 South Korea
 - 9.4.7 Rest of Asia Pacific
- 9.5 South America
 - 9.5.1 Argentina
 - 9.5.2 Brazil
 - 9.5.3 Chile
 - 9.5.4 Rest of South America
- 9.6 Middle East & Africa
 - 9.6.1 Saudi Arabia
 - 9.6.2 UAE
 - 9.6.3 Qatar
 - 9.6.4 South Africa
 - 9.6.5 Rest of Middle East & Africa

10 KEY DEVELOPMENTS

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

11 COMPANY PROFILING

- 11.1 Abbott Laboratories
- 11.2 Beckman Coulter
- 11.3 Becton, Dickinson and Company (BD)
- 11.4 BG Medicine
- 11.5 Bio-Rad Laboratories
- 11.6 Corgenix
- 11.7 Fujirebio
- 11.8 Hologic
- 11.9 Meso Scale Diagnostics (MSD)
- 11.10 Mindray
- 11.11 Ortho Clinical Diagnostics
- 11.12 Pathkind Labs
- 11.13 Qiagen
- 11.14 Randox Laboratories
- 11.15 R-Biopharm AG
- 11.16 Response Biomedical
- 11.17 Roche Diagnostics
- 11.18 Siemens Healthineers
- 11.19 Singulex Inc
- 11.20 SRL Diagnostics
- 11.21 Thermo Fisher Scientific
- 11.22 Trinity Biotech

List Of Tables

LIST OF TABLES

Table 1 Global Cardiac Biomarkers Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Cardiac Biomarkers Market Outlook, By Product Type (2023-2034) (\$MN)

Table 3 Global Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2023-2034) (\$MN)

Table 4 Global Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2023-2034) (\$MN)

Table 5 Global Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2023-2034) (\$MN)

Table 6 Global Cardiac Biomarkers Market Outlook, By Myoglobin (2023-2034) (\$MN)

Table 7 Global Cardiac Biomarkers Market Outlook, By Troponins (2023-2034) (\$MN)

Table 8 Global Cardiac Biomarkers Market Outlook, By Other Product Types (2023-2034) (\$MN)

Table 9 Global Cardiac Biomarkers Market Outlook, By Location of Testing (2023-2034) (\$MN)

Table 10 Global Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2023-2034) (\$MN)

Table 11 Global Cardiac Biomarkers Market Outlook, By Laboratory Testing (2023-2034) (\$MN)

Table 12 Global Cardiac Biomarkers Market Outlook, By Application (2023-2034) (\$MN)

Table 13 Global Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2023-2034) (\$MN)

Table 14 Global Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2023-2034) (\$MN)

Table 15 Global Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2023-2034) (\$MN)

Table 16 Global Cardiac Biomarkers Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 17 Global Cardiac Biomarkers Market Outlook, By End User (2023-2034) (\$MN)

Table 18 Global Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2023-2034) (\$MN)

Table 19 Global Cardiac Biomarkers Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 20 Global Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) (\$MN)

Table 21 Global Cardiac Biomarkers Market Outlook, By Research Institutions

(2023-2034) (\$MN)

Table 22 Global Cardiac Biomarkers Market Outlook, By Other End Users (2023-2034) (\$MN)

Table 23 North America Cardiac Biomarkers Market Outlook, By Country (2023-2034) (\$MN)

Table 24 North America Cardiac Biomarkers Market Outlook, By Product Type (2023-2034) (\$MN)

Table 25 North America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2023-2034) (\$MN)

Table 26 North America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2023-2034) (\$MN)

Table 27 North America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2023-2034) (\$MN)

Table 28 North America Cardiac Biomarkers Market Outlook, By Myoglobin (2023-2034) (\$MN)

Table 29 North America Cardiac Biomarkers Market Outlook, By Troponins (2023-2034) (\$MN)

Table 30 North America Cardiac Biomarkers Market Outlook, By Other Product Types (2023-2034) (\$MN)

Table 31 North America Cardiac Biomarkers Market Outlook, By Location of Testing (2023-2034) (\$MN)

Table 32 North America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2023-2034) (\$MN)

Table 33 North America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2023-2034) (\$MN)

Table 34 North America Cardiac Biomarkers Market Outlook, By Application (2023-2034) (\$MN)

Table 35 North America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2023-2034) (\$MN)

Table 36 North America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2023-2034) (\$MN)

Table 37 North America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2023-2034) (\$MN)

Table 38 North America Cardiac Biomarkers Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 39 North America Cardiac Biomarkers Market Outlook, By End User (2023-2034) (\$MN)

Table 40 North America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2023-2034) (\$MN)

Table 41 North America Cardiac Biomarkers Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 42 North America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) (\$MN)

Table 43 North America Cardiac Biomarkers Market Outlook, By Research Institutions (2023-2034) (\$MN)

Table 44 North America Cardiac Biomarkers Market Outlook, By Other End Users (2023-2034) (\$MN)

Table 45 Europe Cardiac Biomarkers Market Outlook, By Country (2023-2034) (\$MN)

Table 46 Europe Cardiac Biomarkers Market Outlook, By Product Type (2023-2034) (\$MN)

Table 47 Europe Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2023-2034) (\$MN)

Table 48 Europe Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2023-2034) (\$MN)

Table 49 Europe Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2023-2034) (\$MN)

Table 50 Europe Cardiac Biomarkers Market Outlook, By Myoglobin (2023-2034) (\$MN)

Table 51 Europe Cardiac Biomarkers Market Outlook, By Troponins (2023-2034) (\$MN)

Table 52 Europe Cardiac Biomarkers Market Outlook, By Other Product Types (2023-2034) (\$MN)

Table 53 Europe Cardiac Biomarkers Market Outlook, By Location of Testing (2023-2034) (\$MN)

Table 54 Europe Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2023-2034) (\$MN)

Table 55 Europe Cardiac Biomarkers Market Outlook, By Laboratory Testing (2023-2034) (\$MN)

Table 56 Europe Cardiac Biomarkers Market Outlook, By Application (2023-2034) (\$MN)

Table 57 Europe Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2023-2034) (\$MN)

Table 58 Europe Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2023-2034) (\$MN)

Table 59 Europe Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2023-2034) (\$MN)

Table 60 Europe Cardiac Biomarkers Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 61 Europe Cardiac Biomarkers Market Outlook, By End User (2023-2034) (\$MN)

Table 62 Europe Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories

(2023-2034) (\$MN)

Table 63 Europe Cardiac Biomarkers Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 64 Europe Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) (\$MN)

Table 65 Europe Cardiac Biomarkers Market Outlook, By Research Institutions (2023-2034) (\$MN)

Table 66 Europe Cardiac Biomarkers Market Outlook, By Other End Users (2023-2034) (\$MN)

Table 67 Asia Pacific Cardiac Biomarkers Market Outlook, By Country (2023-2034) (\$MN)

Table 68 Asia Pacific Cardiac Biomarkers Market Outlook, By Product Type (2023-2034) (\$MN)

Table 69 Asia Pacific Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2023-2034) (\$MN)

Table 70 Asia Pacific Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2023-2034) (\$MN)

Table 71 Asia Pacific Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2023-2034) (\$MN)

Table 72 Asia Pacific Cardiac Biomarkers Market Outlook, By Myoglobin (2023-2034) (\$MN)

Table 73 Asia Pacific Cardiac Biomarkers Market Outlook, By Troponins (2023-2034) (\$MN)

Table 74 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Product Types (2023-2034) (\$MN)

Table 75 Asia Pacific Cardiac Biomarkers Market Outlook, By Location of Testing (2023-2034) (\$MN)

Table 76 Asia Pacific Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2023-2034) (\$MN)

Table 77 Asia Pacific Cardiac Biomarkers Market Outlook, By Laboratory Testing (2023-2034) (\$MN)

Table 78 Asia Pacific Cardiac Biomarkers Market Outlook, By Application (2023-2034) (\$MN)

Table 79 Asia Pacific Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2023-2034) (\$MN)

Table 80 Asia Pacific Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2023-2034) (\$MN)

Table 81 Asia Pacific Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2023-2034) (\$MN)

Table 82 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Applications

(2023-2034) (\$MN)

Table 83 Asia Pacific Cardiac Biomarkers Market Outlook, By End User (2023-2034) (\$MN)

Table 84 Asia Pacific Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2023-2034) (\$MN)

Table 85 Asia Pacific Cardiac Biomarkers Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 86 Asia Pacific Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) (\$MN)

Table 87 Asia Pacific Cardiac Biomarkers Market Outlook, By Research Institutions (2023-2034) (\$MN)

Table 88 Asia Pacific Cardiac Biomarkers Market Outlook, By Other End Users (2023-2034) (\$MN)

Table 89 South America Cardiac Biomarkers Market Outlook, By Country (2023-2034) (\$MN)

Table 90 South America Cardiac Biomarkers Market Outlook, By Product Type (2023-2034) (\$MN)

Table 91 South America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2023-2034) (\$MN)

Table 92 South America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2023-2034) (\$MN)

Table 93 South America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2023-2034) (\$MN)

Table 94 South America Cardiac Biomarkers Market Outlook, By Myoglobin (2023-2034) (\$MN)

Table 95 South America Cardiac Biomarkers Market Outlook, By Troponins (2023-2034) (\$MN)

Table 96 South America Cardiac Biomarkers Market Outlook, By Other Product Types (2023-2034) (\$MN)

Table 97 South America Cardiac Biomarkers Market Outlook, By Location of Testing (2023-2034) (\$MN)

Table 98 South America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2023-2034) (\$MN)

Table 99 South America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2023-2034) (\$MN)

Table 100 South America Cardiac Biomarkers Market Outlook, By Application (2023-2034) (\$MN)

Table 101 South America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2023-2034) (\$MN)

Table 102 South America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2023-2034) (\$MN)

Table 103 South America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2023-2034) (\$MN)

Table 104 South America Cardiac Biomarkers Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 105 South America Cardiac Biomarkers Market Outlook, By End User (2023-2034) (\$MN)

Table 106 South America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2023-2034) (\$MN)

Table 107 South America Cardiac Biomarkers Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 108 South America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) (\$MN)

Table 109 South America Cardiac Biomarkers Market Outlook, By Research Institutions (2023-2034) (\$MN)

Table 110 South America Cardiac Biomarkers Market Outlook, By Other End Users (2023-2034) (\$MN)

Table 111 Middle East & Africa Cardiac Biomarkers Market Outlook, By Country (2023-2034) (\$MN)

Table 112 Middle East & Africa Cardiac Biomarkers Market Outlook, By Product Type (2023-2034) (\$MN)

Table 113 Middle East & Africa Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2023-2034) (\$MN)

Table 114 Middle East & Africa Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2023-2034) (\$MN)

Table 115 Middle East & Africa Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2023-2034) (\$MN)

Table 116 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myoglobin (2023-2034) (\$MN)

Table 117 Middle East & Africa Cardiac Biomarkers Market Outlook, By Troponins (2023-2034) (\$MN)

Table 118 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Product Types (2023-2034) (\$MN)

Table 119 Middle East & Africa Cardiac Biomarkers Market Outlook, By Location of Testing (2023-2034) (\$MN)

Table 120 Middle East & Africa Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2023-2034) (\$MN)

Table 121 Middle East & Africa Cardiac Biomarkers Market Outlook, By Laboratory

Testing (2023-2034) (\$MN)

Table 122 Middle East & Africa Cardiac Biomarkers Market Outlook, By Application (2023-2034) (\$MN)

Table 123 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2023-2034) (\$MN)

Table 124 Middle East & Africa Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2023-2034) (\$MN)

Table 125 Middle East & Africa Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2023-2034) (\$MN)

Table 126 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 127 Middle East & Africa Cardiac Biomarkers Market Outlook, By End User (2023-2034) (\$MN)

Table 128 Middle East & Africa Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2023-2034) (\$MN)

Table 129 Middle East & Africa Cardiac Biomarkers Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 130 Middle East & Africa Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) (\$MN)

Table 131 Middle East & Africa Cardiac Biomarkers Market Outlook, By Research Institutions (2023-2034) (\$MN)

Table 132 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other End Users (2023-2034) (\$MN)

I would like to order

Product name: Cardiac Biomarkers Market Forecasts to 2034 – Global Analysis By Product Type (B-Type Natriuretic Peptide (BNP), Creatine Kinase-Muscle/Brain (CK-MB) and Other Product Types), By Location of Testing (Point-of-care Testing and Laboratory Testing), Application, End User and By Geography

Product link: <https://marketpublishers.com/r/C87DB9BB05EDEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C87DB9BB05EDEN.html>